Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK1 | P49759 | 2/20 | 0.36 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.30 |
| ▸ | CDC7 | O00311 | 1/20 | 0.30 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25662799 | 0.76 | IKBKB (0.41) | CLK1CDC7DBF4 | |
| SCHEMBL2855389 | 0.68 | CLK1 (0.51) | CLK1CDC7DBF4 | |
| SCHEMBL12822269 | 0.66 | CHEK2 (0.46) | CLK1CYP2A6CDC7DBF4 | |
| SCHEMBL17917464 | 0.66 | EGFR (0.31) | CLK1 | |
| SCHEMBL2313461 | 0.65 | CYP2A6 (0.33) | CYP2A6 | |
| SCHEMBL3588784 | 0.64 | HSD17B10 (0.33) | CLK1CDC7DBF4 | |
| SCHEMBL20120213 | 0.64 | CDC7 (0.30) | CLK1CDC7DBF4 | |
| SCHEMBL25461054 | 0.63 | CLK1 (0.32) | CLK1 | |
| SCHEMBL25662800 | 0.62 | ALDH1A1 (0.54) | CDC7DBF4 | |
| SCHEMBL19436219 | 0.62 | PTGER4 (0.34) | PTGER4CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030203901-A1 | Methods of modulating tyrosine protein kinase function with indolinone compounds | SUGEN, INC. | 2003-10-30 | — | — | US | disclosed |
| US-6514981-B1 | By contacting cells expressing said protein tyrosine kinase with compound | SUGEN, INC. | 2003-02-04 | — | — | US | disclosed |
| EP-1066257-A2 | HETEROCYLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE | Sugen, Inc. (US) | 2001-01-10 | — | — | EP | disclosed |
| WO-1999048868-A9 | HETEROCYCLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE | SUGEN INC (US) | 2000-04-20 | — | — | WO | disclosed |
| WO-1999048868-A2 | HETEROCYCLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE | SUGEN, INC. (US) | 1999-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203901-A1 | Methods of modulating tyrosine protein kinase function with indolinone compounds | LCK, ABL1, PNCK | CLK1 488/4885PTGER4 3584/4885CYP2A6 4366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.